The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Mitsubishi Tanabe Logs 38% Growth in Full-Year Sales, Returns to Profitability on Gilenya Royalties
Mitsubishi Tanabe Pharma saw its sales jump nearly 40% in the fiscal year ended March 2023 by recognizing a bulk sum of royalty payments for its multiple sclerosis drug Gilenya (fingolimod). The royalties had not been logged as revenue in…
To read the full story
Related Article
- Mitsubishi Chemical Ups Full-Year Outlook on Gilenya Royalty Win
February 20, 2023
- Mitsubishi Tanabe Wins Arbitration Case over Gilenya Royalty
February 15, 2023
- Mitsubishi Tanabe Incurs 33 Billion Yen Operating Loss on Medicago Shutdown
February 8, 2023
- Mitsubishi Tanabe’s Core Operating Profit Leaps 60.2% in 1st Half on Priority Products, Overseas Sales
November 10, 2022
- Mitsubishi Tanabe’s Q1 Sales Rise 2.9% on Growth in Japan
August 4, 2022
- Mitsubishi Tanabe Incurs Operating Loss for 3 Years Running, Logs Write-Down on OA Drug
May 16, 2022
- Mitsubishi Tanabe’s 9 Month Sales Rise Fueled by Strong Growth in Stelara
February 4, 2022
- Mitsubishi Tanabe Sales Rise 1.9% in 1st Half on Stelara Growth at Home
November 4, 2021
- Mitsubishi Tanabe Yields 3.9% Sales Increase in Q1 on Radicava’s Overseas Growth
August 5, 2021
- Mitsubishi Tanabe Incurs 6 Billion Yen Operating Loss as Flu Vaccine Project Dropped in US
May 14, 2020
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
- Mitsubishi Tanabe Slashes FY2018 Earnings Forecast
April 25, 2019
- Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe
February 21, 2019
BUSINESS
- Kissei to Run Additional PIII for Spinocerebellar Degeneration Drug
March 17, 2025
- Novel β-Lactamase Inhibitor Nacubactam Safe and Effective: Meiji
March 17, 2025
- AbbVie Files Migraine Med Atogepant in Japan
March 17, 2025
- Zeria’s Hyperkalemia Drug Veltassa Now Available in Japan
March 17, 2025
- Jiho Survey Finds Improvement in Price Revision Rates for Generic Players
March 17, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…